TLR4 and NALP3 inflammasome in the development of endothelial dysfunction in uraemia
European Journal of Clinical Investigation2014Vol. 45(2), pp. 160–169
Citations Over TimeTop 10% of 2014 papers
Susana Martin‐Rodriguez, Carolina Caballo, Gabriela Gutiérrez, Manel Vera, Josep M. Cruzado, Aleix Cases, Ginés Escolar, Maribel Díaz‐Ricart
Abstract
TLR4 and NALP3 inflammasomes, crucial elements of innate immunity, contribute to the development and perpetuation of endothelial dysfunction in response to the uraemic toxicity. These mechanisms constitute potential therapeutic targets to improve endothelial dysfunction and to reduce the increased cardiovascular risk in CKD.
Related Papers
- → NLRP3 licenses NLRP11 for inflammasome activation in human macrophages(2022)57 cited
- → Research Progress of Mitochondrial Mechanism in NLRP3 Inflammasome Activation and Exercise Regulation of NLRP3 Inflammasome(2021)37 cited
- Molecular mechanisms regulating NLRP3 inflammasome activation(2016)
- The inflammasome as future therapeutic target: Development of inflammasome challenge tests(2014)
- → CARD-only proteins (COPs) inhibit uric acid crystal-induced inflammasome activation and ameliorate gout(2023)